The use of drug-eluting stents in ST-elevation myocardial infarction

Khung Keong Yeo, Joost Daemen, Jason H Rogers, Patrick Serruys

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Drug-eluting stents (DES) dramatically lower rates of restenosis in patients undergoing percutaneous coronary interventions. However, their use has extended beyond the initial approved indications into off-label scenarios such as ST-elevation myocardial infarction (STEMI). Multiple retrospective case series and 10 prospective randomised controlled trials have been published on the use of DES in STEMI patients, and these generally show reduced rates of target vessel revascularisation with a neutral effect on mortality. Three meta-analyses show similar findings with the composite endpoint of death, recurrent myocardial infarction, or re-intervention significantly lower in the DES group, although this was largely driven by a decrease in target vessel revascularisation. These studies also demonstrate that DES use in the setting of STEMI is not associated with increased risk of stent thrombosis compared to bare metal stents. In. summary, current data support the efficacy of DES in reducing restenosis and re-intervention in patients who present with STEMI. From a safety standpoint, the use of DES in STEMI does not increase the risk of stent thrombosis, and there is no difference in overall mortality. The use of DES in STEMI patients should be individualised on a case-by-case basis given the importance of compliance with dual antiplatelet therapy.

Original languageEnglish (US)
Pages (from-to)494-500
Number of pages7
JournalEuroIntervention
Volume5
Issue number4
DOIs
StatePublished - Sep 2009

Fingerprint

Drug-Eluting Stents
Stents
Thrombosis
Mortality
Percutaneous Coronary Intervention
ST Elevation Myocardial Infarction
Meta-Analysis
Randomized Controlled Trials
Metals
Myocardial Infarction
Safety

Keywords

  • Drug eluting stent
  • ST-elevation myocardial infarction
  • Stent thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The use of drug-eluting stents in ST-elevation myocardial infarction. / Yeo, Khung Keong; Daemen, Joost; Rogers, Jason H; Serruys, Patrick.

In: EuroIntervention, Vol. 5, No. 4, 09.2009, p. 494-500.

Research output: Contribution to journalArticle

Yeo, Khung Keong ; Daemen, Joost ; Rogers, Jason H ; Serruys, Patrick. / The use of drug-eluting stents in ST-elevation myocardial infarction. In: EuroIntervention. 2009 ; Vol. 5, No. 4. pp. 494-500.
@article{b878551a6fad427fac3dd90d8a406949,
title = "The use of drug-eluting stents in ST-elevation myocardial infarction",
abstract = "Drug-eluting stents (DES) dramatically lower rates of restenosis in patients undergoing percutaneous coronary interventions. However, their use has extended beyond the initial approved indications into off-label scenarios such as ST-elevation myocardial infarction (STEMI). Multiple retrospective case series and 10 prospective randomised controlled trials have been published on the use of DES in STEMI patients, and these generally show reduced rates of target vessel revascularisation with a neutral effect on mortality. Three meta-analyses show similar findings with the composite endpoint of death, recurrent myocardial infarction, or re-intervention significantly lower in the DES group, although this was largely driven by a decrease in target vessel revascularisation. These studies also demonstrate that DES use in the setting of STEMI is not associated with increased risk of stent thrombosis compared to bare metal stents. In. summary, current data support the efficacy of DES in reducing restenosis and re-intervention in patients who present with STEMI. From a safety standpoint, the use of DES in STEMI does not increase the risk of stent thrombosis, and there is no difference in overall mortality. The use of DES in STEMI patients should be individualised on a case-by-case basis given the importance of compliance with dual antiplatelet therapy.",
keywords = "Drug eluting stent, ST-elevation myocardial infarction, Stent thrombosis",
author = "Yeo, {Khung Keong} and Joost Daemen and Rogers, {Jason H} and Patrick Serruys",
year = "2009",
month = "9",
doi = "10.4244/EIJV5I4A78",
language = "English (US)",
volume = "5",
pages = "494--500",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "4",

}

TY - JOUR

T1 - The use of drug-eluting stents in ST-elevation myocardial infarction

AU - Yeo, Khung Keong

AU - Daemen, Joost

AU - Rogers, Jason H

AU - Serruys, Patrick

PY - 2009/9

Y1 - 2009/9

N2 - Drug-eluting stents (DES) dramatically lower rates of restenosis in patients undergoing percutaneous coronary interventions. However, their use has extended beyond the initial approved indications into off-label scenarios such as ST-elevation myocardial infarction (STEMI). Multiple retrospective case series and 10 prospective randomised controlled trials have been published on the use of DES in STEMI patients, and these generally show reduced rates of target vessel revascularisation with a neutral effect on mortality. Three meta-analyses show similar findings with the composite endpoint of death, recurrent myocardial infarction, or re-intervention significantly lower in the DES group, although this was largely driven by a decrease in target vessel revascularisation. These studies also demonstrate that DES use in the setting of STEMI is not associated with increased risk of stent thrombosis compared to bare metal stents. In. summary, current data support the efficacy of DES in reducing restenosis and re-intervention in patients who present with STEMI. From a safety standpoint, the use of DES in STEMI does not increase the risk of stent thrombosis, and there is no difference in overall mortality. The use of DES in STEMI patients should be individualised on a case-by-case basis given the importance of compliance with dual antiplatelet therapy.

AB - Drug-eluting stents (DES) dramatically lower rates of restenosis in patients undergoing percutaneous coronary interventions. However, their use has extended beyond the initial approved indications into off-label scenarios such as ST-elevation myocardial infarction (STEMI). Multiple retrospective case series and 10 prospective randomised controlled trials have been published on the use of DES in STEMI patients, and these generally show reduced rates of target vessel revascularisation with a neutral effect on mortality. Three meta-analyses show similar findings with the composite endpoint of death, recurrent myocardial infarction, or re-intervention significantly lower in the DES group, although this was largely driven by a decrease in target vessel revascularisation. These studies also demonstrate that DES use in the setting of STEMI is not associated with increased risk of stent thrombosis compared to bare metal stents. In. summary, current data support the efficacy of DES in reducing restenosis and re-intervention in patients who present with STEMI. From a safety standpoint, the use of DES in STEMI does not increase the risk of stent thrombosis, and there is no difference in overall mortality. The use of DES in STEMI patients should be individualised on a case-by-case basis given the importance of compliance with dual antiplatelet therapy.

KW - Drug eluting stent

KW - ST-elevation myocardial infarction

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=77950511715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950511715&partnerID=8YFLogxK

U2 - 10.4244/EIJV5I4A78

DO - 10.4244/EIJV5I4A78

M3 - Article

C2 - 19755339

AN - SCOPUS:77950511715

VL - 5

SP - 494

EP - 500

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 4

ER -